KLK3 and posterior cortical atrophy: AR signaling has been demonstrated in all stages of PCa, and one of the downstream targets of AR, prostate-specific antigen (PSA), has been established as a clinical biomarker for PCa diagnosis, prognosis, and progression (reviewed in [17]).